Physician profile

Eric E Simpson

Urology · Dixon, IL

NPI 1134381650

$12,649.58

in general payments reported to CMS, 2019-2025

7 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Consulting Fee$10,908.00
Food and Beverage$297.60

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Genzyme Corporation $10,908.00 2023
Boehringer Ingelheim International Gmbh $1,250.00 2020
Boston Scientific Corporation $310.61 2019-2024 Rezum Generator, Lithoclast, Lithovue
Laborie Medical Technologies Corp. $104.84 2024 Optilume Bph Drug Coated Balloon Catheter
Astellas Pharma US INC $41.89 2019-2020
Pfizer INC. $17.12 2020
Teva Pharmaceuticals USA, INC. $17.12 2023 Austedo

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Eric E Simpson

$12,649.58

in general payments reported 2019-2025

Years
2019-2024
Top company
Genzyme Corporation

https://glasscript.com/doctor/96449/eric-e-simpson

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.